HK1210962A1 - 用於治療動脈粥樣硬化的方法 - Google Patents
用於治療動脈粥樣硬化的方法Info
- Publication number
- HK1210962A1 HK1210962A1 HK15111866.1A HK15111866A HK1210962A1 HK 1210962 A1 HK1210962 A1 HK 1210962A1 HK 15111866 A HK15111866 A HK 15111866A HK 1210962 A1 HK1210962 A1 HK 1210962A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- atherosclerosis
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261678992P | 2012-08-02 | 2012-08-02 | |
US201261695807P | 2012-08-31 | 2012-08-31 | |
US201261695850P | 2012-08-31 | 2012-08-31 | |
PCT/US2013/053008 WO2014022552A1 (en) | 2012-08-02 | 2013-07-31 | Methods for treatment of atherosclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1210962A1 true HK1210962A1 (zh) | 2016-05-13 |
Family
ID=50028503
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15111769.9A HK1210953A1 (zh) | 2012-08-02 | 2015-11-30 | 用於治療動脈粥樣硬化的方法 |
HK15111866.1A HK1210962A1 (zh) | 2012-08-02 | 2015-12-02 | 用於治療動脈粥樣硬化的方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15111769.9A HK1210953A1 (zh) | 2012-08-02 | 2015-11-30 | 用於治療動脈粥樣硬化的方法 |
Country Status (8)
Country | Link |
---|---|
US (5) | US10201585B2 (zh) |
EP (6) | EP2879688A4 (zh) |
JP (5) | JP2015524439A (zh) |
CN (3) | CN104768564A (zh) |
AU (4) | AU2013296494B2 (zh) |
CA (2) | CA2880643A1 (zh) |
HK (2) | HK1210953A1 (zh) |
WO (2) | WO2014022551A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
WO2014022551A1 (en) * | 2012-08-02 | 2014-02-06 | Stealth Peptides International, Inc. | Methods for treatment of atherosclerosis |
EP3586862B1 (en) * | 2012-10-22 | 2021-12-08 | Stealth Peptides International, Inc. | Methods for reducing risks associated with heart failure and factors associated therewith |
WO2015183985A2 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including naphthoquinones and uses thereof |
WO2015183970A1 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including flavonoid and uses thereof |
WO2015183984A2 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including tocopherol and uses thereof |
RU2623876C2 (ru) * | 2014-11-10 | 2017-06-29 | Александр Владимирович Диковский | Фармацевтическая композиция для лечения гиперлипидемии |
WO2016190852A1 (en) * | 2015-05-26 | 2016-12-01 | Stealth Peptides International, Inc. | Therapeutic compositions including chromanyl compounds, variants and analogues thereof, and uses thereof |
WO2017070445A1 (en) * | 2015-10-23 | 2017-04-27 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Methods of treatment of rhabdomyolysis |
US11355245B2 (en) * | 2016-05-03 | 2022-06-07 | International Business Machines Corporation | Identifying and ranking risk factors using trained predictive models |
CA3035875A1 (en) * | 2016-09-20 | 2018-03-29 | Aarhus Universitet | Compounds for treatment of lipoprotein metabolism disorders |
CN107041946A (zh) * | 2017-03-24 | 2017-08-15 | 南京大学 | 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用 |
CN110914287A (zh) | 2017-04-05 | 2020-03-24 | 隐形生物治疗公司 | Boc-d-arg-dmt-lys-(boc)-phe-nh2的结晶盐形式 |
US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
GB202005439D0 (en) | 2020-04-14 | 2020-05-27 | Aurigen Medical Ltd | A device for occlusion of a left a trial appendage of a heart |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4489710A (en) | 1981-06-23 | 1984-12-25 | Xoma Corporation | Composition and method for transplantation therapy |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4625014A (en) | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
JP2005507244A (ja) * | 2001-08-10 | 2005-03-17 | ノバルティス アクチエンゲゼルシャフト | アテローム硬化性病変に結合するペプチド |
HUE027110T2 (en) * | 2003-02-04 | 2016-08-29 | Cornell Res Foundation Inc | Use of an aromatic cationic peptide |
NZ543410A (en) | 2003-05-01 | 2008-07-31 | Cornell Res Foundation Inc | Carrier complexes comprising at least one molecule and an aromatic cationic peptide that can cross cell membranes by an energy-independent mechanism and deliver the molecules inside the cell |
WO2005082023A2 (en) | 2004-02-23 | 2005-09-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
EP4026840A1 (en) | 2005-07-18 | 2022-07-13 | Seagen Inc. | Beta-glucuronide-linker drug conjugates |
US7541340B2 (en) * | 2005-09-16 | 2009-06-02 | Cornell Research Foundation, Inc. | Methods for reducing CD36 expression |
MX2008009591A (es) | 2006-01-30 | 2008-09-24 | Israel Ben David Bryson | Composiciones y metodos para tratar a pacientes con enfermedades cardiovasculares, cerebrovasculares y otras enfermedades vasculares. |
CN101511348B (zh) * | 2006-08-30 | 2012-04-18 | 国立大学法人九州大学 | 含有包封他汀类之纳米颗粒的药物组合物 |
US20090186832A1 (en) * | 2008-01-18 | 2009-07-23 | Shire Llc | Amino acid peptide pro-drugs of phenolic analgesics and uses thereof |
EP2252312B1 (en) * | 2008-02-07 | 2014-04-09 | Cornell University | Methods for preventing or treating insulin resistance |
US20110039766A1 (en) * | 2009-08-12 | 2011-02-17 | Szeto Hazel H | Methods for preventing or treating metabolic syndrome |
EP3292868A1 (en) * | 2009-08-24 | 2018-03-14 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating opthalmic conditions |
EP3332795A1 (en) * | 2010-02-26 | 2018-06-13 | Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
US8697657B2 (en) | 2010-03-15 | 2014-04-15 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
EP2655419A1 (en) | 2010-12-22 | 2013-10-30 | F.Hoffmann-La Roche Ag | Anti-pcsk9 antibodies and methods of use |
WO2014022551A1 (en) * | 2012-08-02 | 2014-02-06 | Stealth Peptides International, Inc. | Methods for treatment of atherosclerosis |
-
2013
- 2013-07-31 WO PCT/US2013/053007 patent/WO2014022551A1/en active Application Filing
- 2013-07-31 EP EP13824883.6A patent/EP2879688A4/en not_active Withdrawn
- 2013-07-31 WO PCT/US2013/053008 patent/WO2014022552A1/en active Application Filing
- 2013-07-31 EP EP18198495.6A patent/EP3485897A1/en not_active Withdrawn
- 2013-07-31 JP JP2015525555A patent/JP2015524439A/ja active Pending
- 2013-07-31 US US14/418,809 patent/US10201585B2/en active Active
- 2013-07-31 EP EP17186931.6A patent/EP3300740A1/en not_active Withdrawn
- 2013-07-31 US US14/418,827 patent/US10188693B2/en active Active
- 2013-07-31 CN CN201380049762.4A patent/CN104768564A/zh active Pending
- 2013-07-31 CN CN201380049785.5A patent/CN104661670A/zh active Pending
- 2013-07-31 CA CA2880643A patent/CA2880643A1/en not_active Abandoned
- 2013-07-31 AU AU2013296494A patent/AU2013296494B2/en active Active
- 2013-07-31 CN CN201910002871.XA patent/CN110090304A/zh active Pending
- 2013-07-31 EP EP13825389.3A patent/EP2879689A4/en not_active Withdrawn
- 2013-07-31 CA CA2880648A patent/CA2880648A1/en not_active Abandoned
- 2013-07-31 EP EP19209275.7A patent/EP3662921A1/en not_active Withdrawn
- 2013-07-31 AU AU2013296493A patent/AU2013296493B2/en active Active
- 2013-07-31 JP JP2015525554A patent/JP2015529655A/ja active Pending
- 2013-07-31 EP EP16174236.6A patent/EP3132800A1/en not_active Withdrawn
-
2015
- 2015-11-30 HK HK15111769.9A patent/HK1210953A1/zh unknown
- 2015-12-02 HK HK15111866.1A patent/HK1210962A1/zh unknown
-
2017
- 2017-10-04 JP JP2017194137A patent/JP2018016637A/ja active Pending
- 2017-10-06 JP JP2017195835A patent/JP2018012726A/ja active Pending
- 2017-12-20 US US15/848,198 patent/US20180344797A1/en not_active Abandoned
- 2017-12-20 US US15/848,712 patent/US20180339012A1/en not_active Abandoned
-
2018
- 2018-03-23 AU AU2018202068A patent/AU2018202068A1/en not_active Abandoned
- 2018-03-27 AU AU2018202197A patent/AU2018202197A1/en not_active Abandoned
-
2019
- 2019-02-08 US US16/271,185 patent/US20200000870A1/en not_active Abandoned
- 2019-03-08 JP JP2019042213A patent/JP2019108389A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1210962A1 (zh) | 用於治療動脈粥樣硬化的方法 | |
HK1219414A1 (zh) | 治療關節炎的方法 | |
EP2773754A4 (en) | Methods of Treatment | |
GB201110095D0 (en) | Method of treatment | |
EP2775837A4 (en) | METHODS OF TREATING HYPERTRIGLYCERIDEMIA | |
EP2717855A4 (en) | PROCESSING METHODS | |
EP2836221A4 (en) | METHOD OF USING CYCLODEXTRIN | |
IL260115A (en) | Methods for treating fibrosis (Leifat) | |
SG11201406118QA (en) | Method for treatment of labor arrest | |
EP2672963A4 (en) | METHOD FOR THE TREATMENT OF MELANOMA | |
HK1209040A1 (zh) | 用於治療前庭毒性的方法 | |
HK1206649A1 (zh) | 治療 的方法 | |
GB201215942D0 (en) | Method of treatent | |
EP2791324A4 (en) | PROCESSING METHOD | |
ZA201503833B (en) | Method of hemoglobin-f determination | |
GB201221032D0 (en) | Method of treatment | |
GB201207894D0 (en) | Method of treatment | |
GB201221118D0 (en) | Methods of treatment | |
GB201216740D0 (en) | Methods of treatment | |
GB201216748D0 (en) | Methods of treatment | |
GB201206330D0 (en) | Methods of treatment | |
GB201206326D0 (en) | Methods of treatment | |
GB201206325D0 (en) | Methods of treatment | |
GB201206324D0 (en) | Methods of treatment | |
GB201321600D0 (en) | Method of cleaning |